(A) Changes in Tregs according to treatment with high-dose IL-2 prior to inclusion. Patients recently treated (< 2 months) was compared with patients treated with high-dose IL-2 >10 months ago.
(B) Changes in the Tregs according to the treatment with Temozolomide (TMZ) prior to inclusion. Patients previously treated with TMZ were compared with TMZ untreated patients.
